Acrobiosystems Co Ltd
SZSE:301080
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.53
66.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Acrobiosystems Co Ltd
Acrobiosystems Co Ltd
Additional Paid In Capital
Acrobiosystems Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Acrobiosystems Co Ltd
SZSE:301080
|
Additional Paid In Capital
¥2.1B
|
CAGR 3-Years
235%
|
CAGR 5-Years
133%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Additional Paid In Capital
¥81.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Additional Paid In Capital
¥4.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Additional Paid In Capital
¥3.3B
|
CAGR 3-Years
95%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Additional Paid In Capital
¥13.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
35%
|
CAGR 10-Years
20%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
See Also
What is Acrobiosystems Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
2.1B
CNY
Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Additional Paid In Capital amounts to 2.1B CNY.
What is Acrobiosystems Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
133%
Over the last year, the Additional Paid In Capital growth was -2%. The average annual Additional Paid In Capital growth rates for Acrobiosystems Co Ltd have been 235% over the past three years , 133% over the past five years .
You don't have any saved screeners yet
